Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -Institution
Dept of Clinical Sciences, Malmö
Address of institution - Street address
Address of institution - City
Address of institution - Postcode
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?
Alzheimer's disease and other dementias
Q1b. When are studies on the above condition(s) expected to become possible?
Q2a. In a single sentence what is the stated aim of the cohort?
MPP started as a primary prevention project at the Medical Clinic in Malmö, with focus on improvement of health of industrial workers
Q2b. What distinguishes this cohort from other population cohorts?
It is one of the largest prospective cohorts in Sweden
Q3a. i) Number of publications that involve use of your cohort to date
Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Nilsson ED, Melander O, Elmståhl S, Lethagen E, Minthon L, Pihlsgård M, Nägga K. Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease. J Alzheimers Dis. 2016 Apr 12;52(3):1047-53
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?
Residents in Malmö, born 1921-1949, initially only men were invited but later on also women
Q4c. Study criteria: what are the exclusion criteria?
Q5. What is the size of the cohort (i.e. how many participants have enrolled)?
More than 15,000 participants
Q6a. Please describe what measures are used to characterise participants
Data are obtained from questionnaries, analyses of blood samples, national and local registers
Q6b. Are there additional measures for participants with a clinical disorder?
Yes, but only in conjunction with the screening
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
If yes please specify
Primarily cancer, cardiovascular diseases and diabetes, Dementia
Q7. What is the study design (select all that apply)?
Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. i) Please enter the data collection start date
Screening started in 1974, but data before that date are obtained from national and local registries
Q10a. ii) Please enter the data collection end date
Currently we have follow-up data until Dec 31, 2014
Q10a. iii) Is data collection for this study
Data analysis ongoing|Closed to new patients
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Q11. Is data collected
Through links to other records or registers (e.g dental records, police records etc)
Other please specify here
National medical and population registers (SoS, SCB), Tax authority etc
Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?
Q13a. Please give information on the format and availability of data stored in a database (1)
Q13a. Please give information on the format and availability of data stored in a database (2)
Q13a. Please give information on the format and availability of data stored in a database (3)
Q13a. Please give information on the format and availability of data stored in a database (4)
Q13b. Please give information on the format and availability of data held as individual records (1)
Data is held as individual records
Q13b. Please give information on the format and availability of data held as individual records (2)
Q13b. Please give information on the format and availability of data held as individual records (3)
Data held on computer based records
Q13b. Please give information on the format and availability of data held as individual records (4)
Please specify language used
Q14a. Is data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?
Apply to PI or co-ordinator at resource|Access committee mechanism|Local/ regional access|National access|International access|Access to industry|Access for pilot studies permitted|Applicant needs to provide separate external ethics approval|Resource has own ethics approval so usually no need for separate external ethics approval
Q15. What data sharing policy is specified as a condition of use?
Data made publicly available after a specified time point
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below:
Living donors: blood derivatives|Living donors: DNA
Q16b. ii) In what form are tissues/samples/DNA supplied?
Secondary samples:(derivatives of primary samples)|Secondary samples: plasma|Secondary samples: DNA
Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Population Cohorts
Member States: Sweden
Diseases: Alzheimer's disease & other dementias
Database Categories: N/A
Database Tags: N/A
Export as PDF